Document Detail


Monitoring the effect of heparin by measurement of activated clotting time during and after percutaneous transluminal coronary angioplasty.
MedLine Citation:
PMID:  2178656     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The anticoagulant effect of heparin during percutaneous transluminal coronary angioplasty was monitored by measurements of the activated clotting time in two studies that compared the effects of a single bolus of heparin with those of a bolus of heparin combined with a continuous infusion of the drug. In a preliminary study 40 patients received a single heparin bolus of 10,000 units (protocol I) and a further 40 patients received both a heparin bolus of 10,000 and a continuous infusion of heparin at a rate of 2000 units per hour (protocol II). During the first 45 minutes, nine patients (23%) in protocol I but only two patients (5%) in protocol II were found to be inadequately anticoagulated. For 24 hours after angioplasty both groups received an infusion of heparin at the rate of 2000 units per hour which led to consistent anticoagulation in 73 (91%) of patients. In a subsequent randomised study, 40 patients received heparin according to either protocol I or II. Protocol II was again found to lead to a higher rate of adequate anticoagulation. During the first 60 minutes 11 patients (55%) in protocol I but only three patients (15%) in protocol II were inadequately anticoagulated. In addition, the activated clotting time of arterial blood in the first 30 minutes was significantly higher than that of venous blood in 70% of the patients. A bolus of heparin (10,000 units) together with an infusion of 2000 units per hour should be routinely given during coronary angioplasty. The effects of heparin, which can vary considerably from patient to patient, should be monitored by the measurement of the activated clotting time of arterial blood.
Authors:
B Rath; D H Bennett
Related Documents :
3561706 - Cerebral thromboembolism due to antithrombin iii deficiency in two children.
12353306 - Pai-1 gene 4g/5g genotype: a risk factor for thrombosis in vessels of internal organs.
7705156 - Untreated patients with pulmonary embolism. outcome, clinical, and laboratory assessment.
9093766 - Lupus anticoagulant and thrombosis: role of von willebrand factor multimeric forms.
18556626 - Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients ...
14570626 - The prevalence of preoperative diastolic filling abnormalities in geriatric surgical pa...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  British heart journal     Volume:  63     ISSN:  0007-0769     ISO Abbreviation:  Br Heart J     Publication Date:  1990 Jan 
Date Detail:
Created Date:  1990-04-16     Completed Date:  1990-04-16     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  0370634     Medline TA:  Br Heart J     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  18-21     Citation Subset:  AIM; IM    
Affiliation:
Regional Cardiac Centre, Wythenshawe Hospital, Manchester.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Angina Pectoris / therapy
Angioplasty, Transluminal, Percutaneous Coronary / adverse effects*
Coronary Disease / prevention & control*
Coronary Thrombosis / etiology,  prevention & control*
Female
Heparin / administration & dosage,  therapeutic use*
Humans
Infusions, Intra-Arterial
Infusions, Intravenous
Injections, Intra-Arterial
Male
Middle Aged
Randomized Controlled Trials as Topic
Whole Blood Coagulation Time
Chemical
Reg. No./Substance:
9005-49-6/Heparin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Importance of affects for diagnosis, prognosis and therapy
Next Document:  Short term haemodynamic effects of converting enzyme inhibition before and after eating in patients ...